| 摘要 |
<p>New therapeutic agents contain (a) nicotinates of biguanides of formula R1R2N-C(=NH)-NH-C(=NH2 (I) (where R1 is 1-5C alkyl or beta-phenethyl in which the aromatic residue may be substd. by a lower alkyl gp. or a halogen atom, and R2 is H or lower alkyl), in combination with (b) the magnesium salt of clofibric acid. The agents ae hypolipaemic agents. Use of nicotinic acid in the form of its salts with (I) gives improved glucose tolerance. The hypolipaemic activity of the nicotinic acid salt is potentiated by the magnesium salt of clofibric acid. and the Mg ions promote fibrinolysis and exert central sedative and smooth muscle relaxant effects. The nicotinic acid content is reduced, thus avoiding the flushing which could otherwise occur. In an example, tablets for oral admin. contain 40 mg phenformin mononicotinate and 450 mg (b).</p> |
